Only 2 are in the Magnificent Seven

It was a big rebound year for stocks. The S & P 500 gained 24%, while the Dow rose 14% and the tech-heavy Nasdaq rose more than 43%. All three major averages were coming off big losses in 2022. Our portfolio of 33 stocks also bounced back. Throughout the year, we held onto our conviction … Read more

Nvidia has tripled this year. Cramer says the stock is still too cheap

Nvidia — the star of the S & P 500 in 2023 — enters 2024 even cheaper than it was a year ago. Shares of the chipmaker, which more than tripled this year, are now valued at roughly 25 times forward earnings, down from 34 at the end of 2022, according to FactSet data. The … Read more

Obesity and Alzheimer’s drugs pack one-two punch to lift Eli Lilly

Investor optimism for Eli Lilly ‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be the same old story. Shares of Eli Lilly have taken a breather over the past three months, as investors book profits in the top performer … Read more

Strong holiday spending is great news for 3 of our stocks

Holiday spending held up this year, despite all the economic uncertainty and high inflation. It’s welcome news for a few of our stocks. New data released Tuesday shows U.S. retail sales increased 3.1% year over year from Nov. 1 through Dec. 24, according to Mastercard SpendingPulse . The report, which excludes auto sales and is … Read more

Top 10 things to watch in the stock market Tuesday

Our 10 things to watch Tuesday, Dec. 26 1. Stocks rose slightly to kick off the final trading week of the year, as longer-dated bonds pull back slightly. Santa Clause rally in the making? We closed out last week with the S & P Short Range Oscillator at 6.54%, which means we are still technically … Read more

Why Pfizer’s stumble in the obesity market is a boon for Eli Lilly

Pfizer (PFE) has suffered another setback in its efforts to develop a weight-loss pill — and that’s good news for Club holding Eli Lilly (LLY) as it looks to maintain an edge in the fast-growing obesity-treatment market. Pfizer said Friday it will discontinue its twice-daily weight-loss pill, danuglipron, after patients in a mid-stage trial experienced … Read more

A tech-heavy portfolio can be still considered diversified. Here’s how

Here’s our Club Mailbag email [email protected] — so you send your questions directly to Jim Cramer and his team of analysts. We can’t offer personal investing advice. We will only consider more general questions about the investment process or stocks in the portfolio or related industries. This week’s question: Can you discuss how to weigh … Read more

Jim Cramer’s top 10 things to watch in the stock market Monday

My top 10 things to watch Monday, Dec. 4 1. U.S. stocks are lower in premarket trading, with S & P 500 futures down 0.54%. The move comes after five-straight weeks of gains for equities — and here’s how I make sense of the tremendous rally we’ve seen. Meanwhile, bond yields pull back, with that … Read more

The top 10 things to watch in the stock market Wednesday

The 10 things to watch Wednesday, Dec. 6 1. U.S. stocks are higher in premarket trading Wednesday, with S & P 500 futures up 0.45% after back-to-back days of losses. The move comes amid increasing signs the labor market is loosening, suggesting the Federal Reserve’s interest-rate hikes are succeeding in cooling the economy. U.S. private … Read more

Ford’s strong hybrid sales show the company needs to pivot to increase profits

Exploding consumer demand for Ford (F) hybrids last month is further evidence the automaker should pivot its production focus and scale back on electric vehicles. Hybrids “make a ton of money,” Jim Cramer said Monday after Ford reported a 75% year-over-year surge in hybrid sales in November to roughly 12,100 vehicles. EV sales were also … Read more